Companies in
Pharmaceutical Industry

Nemosia AG

Research & Development · Winterthur · Since 2022

The core activity of Nemosia is the development of solutions to combat neurodegenerative diseases, particularly through the development of radiopharmaceuticals and the application of Positron Emission Tomography (PET) for the diagnosis and treatment of brain disorders.

Neovii Pharmaceuticals AG

Pharmaceutical Industry · Jona · Since 2013

Neovii Pharmaceuticals AG is an independent global biopharmaceutical company that develops and brings to market polyclonal antibody immunosuppressive therapies. Its research and products focus on transplantation medicine, stem cell transplantation, and hematology/oncology and immune disorders; the product range includes Grafalon®.

Bioviida Ventures GmbH

Pharmaceutical Industry · Jona · Since 2023

Neovii Biopharmaceuticals GmbH is a biopharmaceutical company that develops and markets polyclonal antibody therapies for transplantation medicine and hematology/oncology. The company supports research in solid-organ and stem-cell transplantation, immune disorders and hemato-oncological conditions, and its portfolio includes the polyclonal antibody product Grafalon®.

Neurocrine Switzerland GmbH

Pharmaceutical Industry · Allschwil · Since 2023

Neurocrine Switzerland GmbH conducts research and development of treatments for neurological, neuroendocrine and neuropsychiatric disorders. The organisation’s portfolio includes approved medicines for conditions such as tardive dyskinesia, chorea associated with Huntington’s disease, congenital adrenal hyperplasia, endometriosis and uterine fibroids, and it maintains a pipeline with compounds in mid‑to‑late stage clinical development.

NOBEL Pharma Schweiz AG

Pharmaceutical Industry · Rotkreuz · Since 2018

The core activity of NOBEL Pharma Schweiz AG is the development, manufacture and marketing of pharmaceutical products, in particular generics and OTC products, which are used in various therapeutic areas such as allergy, flu/cold, cardiovascular, gastrointestinal, nervous system, pain/inflammation, metabolism and urogenital tract.

Noema Pharma AG

Pharmaceutical Industry · Basel · Since 2020

The core activity of Noema Pharma is the development and marketing of therapeutics for central nervous system (CNS) disorders. The company focuses on developing treatments for rare and severe brain and nervous system diseases, such as Tuberous Sclerosis, Trigeminal Neuralgia, Tourette's Syndrome, and Menopause symptoms.

Nonex GmbH

Medical Technology Industry · Bern · Since 2024

Nonex GmbH develops biodegradable technologies and products for applications in food, cosmetics, healthcare, cleaning, and packaging. Its offerings include nano-fiber-based drug delivery systems, edible biopolymer food products, biodegradable gels for beauty and cleaning, and services such as project management, consulting and research communication for bio- and medical-technology projects.

Noorik Biopharmaceuticals AG

Pharmaceutical Industry · Basel · Since 2010

Noorik Biopharmaceuticals AG is a privately owned drug development company focused on repurposing existing drugs and conducting research and development. It is developing a micro-dose formulation of ambrisentan, an endothelin receptor antagonist, for indications including severe COVID-19 pneumonia, portal hypertension and pulmonary arterial hypertension, and has developed novel oral and parenteral formulations, holds second medical use patents and is seeking co-development partners.

NORIS PHARMA AG

Cosmetics Industry · Zurich · Since 2023

NORIS PHARMA AG develops proprietary OTC products, medical devices and dietary supplements and provides consultancy services for the medical, pharmaceutical and healthcare sectors. The company supports the full product development and launch process, including market analysis, formulation proposals, supplier selection, production oversight and product registration.

NovaGo Therapeutics AG

Pharmaceutical Industry · Schlieren · Since 2024

The core activity of Neurimmune (or NovaGo) is the development of therapeutic antibodies for the treatment of neurodegenerative and other diseases, particularly Alzheimer's, Parkinson's, tauopathies, and amyotrophic lateral sclerosis. The company focuses on the discovery, development, and clinical testing of antibody-based medications.

NovaPharm SA

Pharmaceutical Industry · Epalinges · Since 2008

NovaPharm SA provides consulting, services and trading in the healthcare sector, including market access, distribution, sourcing and regulatory compliance. The company conducts purchase and resale of medicines and health products and holds a Swissmedic authorization for trading.

Novaremed AG

Research & Development · Basel · Since 2017

Novaremed AG develops non-opioid pharmaceutical therapies for the treatment of chronic neuropathic pain and peripheral neuropathies. Its lead candidate, nispomeben (NRD.E1), is an orally active small molecule in clinical development and is being evaluated in an NIH-supported Phase 2b trial for painful diabetic peripheral neuropathy with FDA Fast Track designation; an earlier-stage candidate, MP-101, targets prevention of chemotherapy-induced peripheral neuropathy.

Novartis AG

Pharmaceutical Industry · Basel · Since 1996

Novartis AG researches, develops, manufactures and commercializes pharmaceutical medicines and gene therapies, operating across therapeutic areas including oncology, neuroscience, immunology and cardiovascular, renal and metabolic diseases. The company also provides clinical trials, medical information and managed access programs for patients and healthcare professionals.

Novartis International AG

Pharmaceutical Industry · Basel · Since 1989

Novartis International AG is a medicines company that researches, develops and commercializes prescription pharmaceuticals, biologics and advanced therapy platforms. The company focuses on therapeutic areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience and oncology, and operates technology platforms such as chemistry, biotherapeutics, xRNA, radioligand therapy and gene and cell therapy.

NOVARTIS FORSCHUNGSSTIFTUNG

Pharmaceutical Industry · Basel · Since 1989

Novartis Foundation

Pharmaceutical Industry · Basel · Since 1979

The core activity of Novartis is the development, manufacture and marketing of pharmaceuticals and healthcare products, with a focus on innovation and access to healthcare, particularly in the areas of malaria, neglected tropical diseases and non-communicable diseases such as sickle cell anemia.

Novartis Pharma Schweiz AG

Pharmaceutical Industry · Rotkreuz · Since 1986

Novartis Pharma Schweiz AG is a pharmaceutical company that conducts research and development, manufactures and markets medicines, and provides information and services for patients and healthcare professionals.

Novartis Pharma Schweizerhalle AG

Pharmaceutical Industry · Pratteln · Since 1938

Novartis Pharma Services AG

Pharmaceutical Industry · Basel · Since 1991

Novartis Pharma Stein AG

Pharmaceutical Industry · Stein Ag · Since 1997

Novartis Stiftung für Mensch und Umwelt

Pharmaceutical Industry · Basel · Since 1989

Novartis Stiftung für Mensch und Umwelt supports Novartis’ social and environmental initiatives, including sponsorship, donations and community engagement. The foundation also addresses health, safety and environmental protection measures and promotes transparency in ethics and compliance.

NOVELTY PHARMA GALENICAL DEVELOPMENT AND DOCUMENTATION SA

Research & Development · Cadempino · Since 2003

The core activity of Novelty Pharma is the production of customer-specific, tailor-made effervescent tablets.

NOVIPHARMA SA

Research & Development · Nyon · Since 2005

NOVIPHARMA SA manages the global supply chain for innovative medicines developed through Bial’s research and development activities. The company serves as Bial’s strategic platform for worldwide growth and is authorised by Swissmedic for wholesale and foreign trade of drugs.

NovoLytiX GmbH

Pharmaceutical Industry · Witterswil · Since 2020

NovoLytiX GmbH supplies immunoassays (RIA and ELISA) for measurement of melatonin in saliva, serum and plasma, and provides related assays such as 6‑sulfatoxymelatonin, vasopressin, caffeine and cortisol.

Nuclidium AG

Pharmaceutical Industry · Basel · Since 2018

The core activity of Nuclidium AG is the development, manufacture and marketing of radiopharmaceutical products, in particular copper-based radiopharmaceuticals, for cancer diagnosis and therapy.

Numab Therapeutics AG

Research & Development · Horgen · Since 2016

The core activity of Numab Therapeutics AG is the development and research of immunological and immuno-oncological drugs, in particular multispecific biotherapeutics. The company focuses on the development of next-generation drugs and platforms for the treatment of diseases, specializing in the development of proprietary technologies such as λ-Cap and MATCH.

NUTRAPHAR SA

Pharmaceutical Industry · Chez-Le-Bart · Since 2022

The core activity of Nutraphar is the development and provision of innovative solutions in the pharmaceutical industry, particularly in the areas of biotechnology, vaccines and nanostructured materials.

Nutrimed AG

Pharmaceutical Industry · Basel · Since 1986

The core activity of Nutrimed LTD is the development, manufacture and marketing of dietary supplements, particularly vitamins and minerals such as magnesium, vitamin B12, vitamin D and zinc, in various forms such as effervescent tablets and soft capsules.

Octapharma AG

Pharmaceutical Industry · Lachen Sz · Since 1999

The core activity of Octapharma is the development, production and marketing of healthcare solutions, in particular plasma-based medicines that improve patients' lives. This includes plasma collection, research and development of therapeutic proteins, production of medicines and clinical testing of products. The company operates its own plasma donation centers and invests in expanding its network to ensure the availability of plasma.

OctoSwiss GmbH

Pharmaceutical Industry · Basel · Since 2018

The core activity of OctoSwiss GmbH is the development, manufacture and marketing of pharmaceutical products, in particular medicines for the treatment of various diseases such as parasitic infections, bacterial infections, gastrointestinal disorders, respiratory diseases, hormonal disorders and other diseases. In addition, the company also offers advisory services and pharmacovigilance services.

ODI Pharma Schweiz AG

Pharmaceutical Industry · Zug · Since 2018

The core activity of ODI Pharma is the development, production and distribution of medical cannabis in Europe. The company focuses on the manufacture of pharmaceutical cannabis products in strict compliance with EU GMP and GDP standards and supplies them to pharmacies, clinics and hospitals in 23 European countries. In addition, ODI Pharma also offers white-label services, where the company manufactures and delivers high-quality products for other brands.

Olympic Therapeutics AG

Research & Development · Zug · Since 2008

Olympic Therapeutics AG develops bacteriophages for the treatment of MRSA and other bacterial infections, focusing on research and development of therapeutic phage candidates. The company’s activities include identification and development of phage candidates, intellectual property protection, and preparation for clinical development and commercialization.

Oncoteq AG

Pharmaceutical Industry · Cham · Since 2022

The core activity of Oncoteq AG is the development of oncological treatments using artificial intelligence (AI) in the clinical stage.

OpenVial Sàrl

Pharmaceutical Industry · Fribourg · Since 2022

OpenVial Sàrl develops, manufactures and markets packaging systems for injectable pharmaceutical solutions. Its products include oVi, a sterile, pre‑tested, double‑packed Type 1 borosilicate vial system intended for early‑stage research and R&D in pharmaceutical and biotechnology applications, with batch documentation and testing for sterility, endotoxins and particulate control.

Opterion Health AG

Pharmaceutical Industry · Muttenz · Since 2012

The core activity of Opterion Health AG is the development and marketing of a new, non-glucose-based osmotic agent for peritoneal dialysis (PD) in patients with end-stage renal disease. The company focuses on creating an innovative product that reduces the metabolic side effects of conventional glucose-based solutions and improves the quality of life for patients.

ORACTIVE SWISS AG

Pharmaceutical Industry · Zug · Since 2021

The core activity of ORACTIVE Swiss AG is the development of 'Super Generics', i.e. innovative medicines based on established active pharmaceutical ingredients (APIs), specifically designed to combat modern lifestyle diseases.

Orchard Therapeutics (Switzerland) GmbH

Research & Development · Zug · Since 2023

OrchestratePharma GmbH

Pharmaceutical Industry · Baar · Since 2023

OrchestratePharma GmbH is a drug development company focused on drug repurposing (DRPx) of known molecular entities, notably fexofenadine. It is developing a topical product, FexoTopic (OP2101), for treatment of mild to moderate atopic dermatitis and pursues strategic partnerships with CROs, data-science and DRPx collaborators to accelerate development.

Organon Pensionskasse Schweiz

Pharmaceutical Industry · Lucerne · Since 2021

Orgenesis Switzerland Sàrl

Pharmaceutical Industry · Lausanne · Since 2022

Orgenesis Switzerland Sàrl develops and implements the POCare platform for cell and gene therapies, focusing on process development, validation and automated closed‑loop bioprocessing units (OMPUL™) for decentralized point‑of‑care production.

Orio Therapeutics SA

Pharmaceutical Industry · Monthey · Since 2023

Orio Therapeutics' core activity is the development of protein-based therapeutics for regenerative medicine, particularly for the treatment of heart attacks. The company focuses on modifying therapeutic proteins to control their localization and delivery, thereby improving efficacy and reducing dosing.

OrPha Swiss GmbH

Pharmaceutical Industry · Küsnacht Zh · Since 2003

The core activity of OrPha Swiss is the development, manufacture and marketing of medicines for rare diseases (Orphan Diseases) and niche areas, particularly in the fields of pulmonary hypertension, infectiology and intensive and emergency medicine.

Osmopharm SA

Research & Development · Bedano · Since 1994

The core activity of Osmopharm SA is the development and production of modified oral dosage forms, particularly in pellet, tablet or resin form, using advanced galenic technologies such as coating, extrusion-spheronization and ion exchange. The company also offers services such as the manufacture of hard gelatin capsules or tablets, capsule filling and packaging of pharmaceuticals. Additionally, Osmopharm supports its customers in preparing registration applications and conducting regulatory activities.

Otsuka Pharmaceutical (Switzerland) GmbH

Research & Development · Glattbrugg · Since 2013

The core activity of Otsuka Pharmaceutical Europe Ltd. is the development, manufacture and marketing of pharmaceutical products and nutritional supplements (Nutraceuticals) to improve the health and well-being of people worldwide.

Packgene Biotech AG

Research & Development · Zug · Since 2024

Packgene Biotech AG provides contract research and manufacturing services for cell and gene therapies, including AAV and lentivirus packaging, mRNA/LNP and plasmid production, vector design, analytical testing and GMP manufacturing services.

Palto Therapeutics AG

Pharmaceutical Industry · Allschwil · Since 2020

Palto Therapeutics AG develops novel formulations for biological drugs, focusing on oligonucleotide-based therapeutics such as siRNAs to enable targeted cellular uptake and cytoplasmic activation. The company designs proprietary formulation and delivery strategies to address in vivo stability and achieve tissue- or cell-type-specific distribution.

PATHELEN HEALTH CARE AG

Medical Technology Industry · Rorschach · Since 2014

PATHELEN HEALTH CARE AG is a biotechnology company that develops therapies for wound care and infection management, focusing on materials that physically adsorb wound exudate and address biofilms and resistant pathogens. Its portfolio includes the product PATHELEN® HYBRID and further developments such as a gel for chronic wound aftercare and a suspension for treating cystitis caused by resistant germs.